A Phase I Open Label Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose
During the first 28 day treatment cycle
No
United States: Food and Drug Administration
COU-NOS-001
NCT00912899
November 2007
July 2010
Name | Location |
---|---|
Weill Medical College of Cornell University | New York, New York 10021 |
Columbia Presbyterian Hospital | New York, New York 10032 |
St. Vincent's Comprehensive Cancer Center | New York, New York 10011 |
UCLA | Los Angeles, California 90095 |